Skip to main content

Table 1 Baseline characteristics of the patient population

From: Does age alone negatively predict the outcome of sacral neuromodulation? A single-centre retrospective observational study

Category

Overall population

n = 95 pts

A: Patients < 70 years

n = 75 pts

B: Patients ≥70 years

n = 20 pts

P-value

“patients < 70 years” versus “patients ≥70 years”

Patient age [years] (range)

53.2 ± 16.1 (17–76)

48 ± 13.6 (17–69)

73 ± 2.0 (70–76)

Gender (%):

• Male (%)

36 (38)

29 (39)

7 (35)

0.764*

• Female (%)

59 (62)

46 (61)

13 (65)

BMI [kg/m2] (range)

27.5 ± 5.4 (16.2–43.2)

27.5 ± 5.6 (16.2–43.2)

27.3 ± 4.4 (19.3–36.2)

0.872**

ASA score (%):

• ASA 1 (%)

6 (6)

5 (7)

1 (5)

Lack of items.

• ASA 2 (%)

64 (67)

51 (68)

13 (65)

• ASA 3 (%)

25 (26)

19 (25)

6 (30)

CCI score (range)

0.47 ± 0.766 (0–3)

0.45 ± 0.776 (0–3)

0.55 ± 0.759 (0–3)

0.620**

Diabetes mellitus (%)

9 (9.4)

7 (9.3)

2 (10)

Lack of items.

ISAR score (%):

• ISAR score 0

45 (47)

39 (52)

6 (30)

Lack of items.

• ISAR score 1

38 (40)

28 (37)

10 (50)

• ISAR score 2

8 (8)

6 (8)

2 (10)

• ISAR score 3

4 (4)

2 (3)

2 (10)

Cause of bladder function disorder (%):

• OAB (%)

48 (51)

35 (47)

13 (65)

0.145*

• Retention (%)

47 (49)

40 (53)

7 (35)

OAB classification (%):

• OAB dry (%)

16 (33)

11 (31)

5 (39)

0.645*

• OAB wet (%)

32 (67)

24 (69)

8 (61)

Prior OAB therapy (%):

• Oral medication (%)

48 (48/48, 100)

35 (35/35, 100)

13 (13/13, 100)

0.249*#

• Onabotulinumtoxin A (%)

23 (23/48, 48)

15 (15/35, 43)

8 (8/13, 62)

Prior retention therapy (%):

Oral medication (%)

8 (8/47, 17)

8 (8/40, 20)

0

Lack of items.

Catheterization (%)

39 (39/47, 83)

32 (32/40, 80)

7 (7/7, 100)

  1. (n = 95 patients); the mean ± standard deviation (range) or percentage
  2. *Chi-square test (α = 0.05), **T-test unpaired (α = 0.05), #Onabotulinumtoxin vs. no onabotulinumtoxin